Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer

被引：0
|
作者：
Heller, Simon
Sugawara, Tatsuo
Nevedomskaya, Ekaterina
Baumgart, Simon J.
Nguyen, Holly
Corey, Eva
Bohme, Annika
von Ahsen, Oliver
Politz, Oliver
Haendler, Bernard
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 11期
关键词：
D O I：
10.1158/1538-7445.PRCA2023-B065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B065
引用
收藏
页数：3
相关论文
共 50 条
  • [11] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [12] Preclinical studies of the combination of dual PI3K/Akt/mTOR inhibitors with radiotherapy to overcome radioresistant prostate cancer
    Chang, Lei
    Graham, Peter H.
    Hao, Jingli
    Jie Ni
    Bucci, Joseph
    Cozzi, Paul J.
    Kearsley, John H.
    Li, Yong
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S50 - S50
  • [13] PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
    Wu, P.
    Hu, Y-Z
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (35) : 4326 - 4341
  • [14] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
  • [15] High efficacy of combination therapy of PI3K/AKT inhibitors with androgen deprivation in prostate cancer.
    Marques, Rute
    Aghai, Ashraf
    Stuurman, Debra
    de Ridder, Corrina
    Boer, Agnes
    Hoeben, Sander
    Trapman, Jan
    van Weerden, Wytske M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [16] Combining metabolic starvation and PI3K/AKT/mTOR pathway inhibition to chemosensitize prostate cancer cells.
    Bevilacqua, Annamaria
    Calastretti, Angela
    Gatti, Giuliana
    Canti, Gianfranco
    CANCER RESEARCH, 2018, 78 (16) : 52 - 53
  • [17] PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells
    Kaarbo, Mari
    Mikkelsen, Oyvind Loveseter
    Malerod, Lene
    Qu, Su
    Lobert, Viola H.
    Akgul, Gulcan
    Halvorsen, Thomas
    Maelandsmo, Gunhild M.
    Saatcioglu, Fahri
    CELLULAR ONCOLOGY, 2010, 32 (1-2) : 11 - 27
  • [18] Dual Targeting of Androgen Receptor and PI3K/AKT/mTOR Pathways in Prostate Cancer By Salinomycin: A Contrast to Rapamycin
    Mirkheshti, Nooshin
    Chatterjee, Bandana
    Song, Chung Seog
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [19] Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer Cells
    Liu, Liangliang
    Dong, Xuesen
    PLOS ONE, 2014, 9 (10):
  • [20] Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models
    Rossetti, Stefano
    Broege, Aaron
    Sen, Adrish
    Khan, Salmaan
    MacNeil, Ian
    Molden, Jhomary
    Kopher, Ross
    Schulz, Stephen
    Laing, Lance
    NPJ BREAST CANCER, 2024, 10 (01)
12345